Hematologic Malignancies Market Size, Share and Trends Analysis, By Type (Leukemia, Lymphoma, Myeloma, and Others), By Diagnosis (Blood Tests, Biopsy, and Imaging Tests), By Treatment Type, By Route of Administration (Oral, Parenteral, and Others), By End-Use, and By Region, Forecast 2025-2032

Hematologic Malignancies Market Overview and Key Insights:

The hematologic malignancies market size reached USD 70.84 billion in 2024 and is expected to register a revenue CAGR of 8.4% during the forecast period. Haematological malignancies are myeloid and lymphatic cancers that result from a disturbance in normal hematopoietic function. They are divided into numerous common subtypes, which include leukaemia, multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma.

Market Drivers:

Rising incidence and prevalence of hematologic cancers is a key factor driving the market growth. According to the Lymphoma and Leukaemia Society, every three minutes, one individual in the United States is diagnosed with leukemia, lymphoma, or myeloma. An estimated 187,740 persons in the United States will be diagnosed with leukemia, lymphoma, or myeloma by 2024, and new instances of leukemia, lymphoma, and myeloma are predicted to make up 9.4 percent of the estimated 2,001,140 new cancer cases diagnosed in the United States in 2024.

Germline predisposition syndromes are becoming more widely recognized in people with hematologic malignancies (HM). It is estimated that genetic predisposition accounts for 10% to 20% of HM cases during life. According to studies of pediatric HM/bone marrow failure (BMF) cohorts, underlying germline pathogenic mutations explain 10% to 30% of diagnoses, generally in genes such as SAMD9, SAMD9L, GATA2, Fanconi anemia pathway genes, and telomere biology genes.  The incidence of inherited predisposition syndromes in adult-onset HM/BMF is unknown, but evidence is accumulating as genetic testing becomes available to a larger number of affected people. Recent research suggests that about 10% to 20% of familial myeloid malignancies, such as acute myeloid leukemia and myelodysplastic syndrome (MDS), are inherited.

On June 2025, Incyte announced that the FDA has approved Monjuvi (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide, for the treatment of adult patients with relapsed or refractory follicular lymphoma. Tafasitamab contains an XmAb-engineered Fc domain that promotes B-cell lysis via apoptosis and immunological effector mechanisms such as Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

Market Opportunity:

Integration of AI and big data in hematologic malignancy diagnostics and patient management acts as opportunities for hematologic malignancies market. Artificial intelligence (AI) has emerged as a transformative tool in this endeavor, with the potential to change both drug repurposing for infectious diseases and hematology.

Convolutional neural networks (CNNs), a type of deep learning model, have emerged as a powerful tool in this field, enabling researchers to achieve high accuracy in recognizing and classifying distinct blood cell types. In addition to analyzing sickle cell disease, researchers are also using AI-powered methods to quantify cellular characteristics across various other hematological disorders.

For example, in myelodysplastic syndromes (MDS), a group of conditions marked by abnormal blood cell formation, scientists employ AI algorithms to examine bone marrow cell morphology and predict disease progression and response to therapy. In cases of acute myeloid leukemia (AML), researchers use AI-driven analysis of blast cell morphology to identify distinct subtypes with different prognoses and treatment responses.

On December 2024, ConcertAI and NeoGenomics have unveiled a collaborative software-as-a-service solution for hematological malignancies, including research analytics, clinical trial design, and clinical trial operational optimization. CTO-H offers a research data solution with unmatched scale, longitudinality, and biomarker depth. ConcertAI will use the agreement to deploy CTO-H as a SaaS service within its CARAai cloud. NeoGenomics will offer services for interpreting specialist biomarkers and tests, as well as access to unique clinical knowledge to ensure the highest level of confidence in analysis, study designs, and interpretations.

Recent Trends:

Emerging trends include precision medicine, radioimmunotherapy, Next-Generation Sequencing (NGS), Artificial Intelligence (AI) and machine learning, and advancements in stem cell transplantation.

Researchers have demonstrated that whole-genome sequencing (WGS) is an effective alternative because it provides comprehensive genomic profiling and detects all relevant genetic abnormalities, including chromosomal changes, structural variants, and cryptic mutations that traditional methods such as cytogenetics and fluorescence in situ hybridization (FISH) often miss.

WGS simplifies the diagnostic process by combining several tests into a single assay within a uniform workflow, allowing laboratories to deliver results in about five days. Although experts have long considered WGS an expensive test, decreasing sequencing costs are making it more economically viable. Additionally, the National Comprehensive Cancer Network has included WGS in its guidelines for AML/MDS management, and Medicare now covers the technique.

On October 2023, NeoGenomics, Inc., a leading oncology testing services provider, has announced the commercial availability of two new tests, adding to its cancer range of revolutionary solutions. These include Neo Comprehensive – Heme Cancers, a next-generation sequencing (NGS) panel providing a comprehensive genomic profile of hematopoietic malignancies, and the early-stage Non-Small Cell Lung Cancer (NSCLC) Panel, a therapy selection panel designed exclusively for patients with early-stage NSCLC. It expands NeoGenomics’ wide test menu for heme testing, particularly the NGS portfolio, and solidifies the company’s position as a leading laboratory in heme oncology services.

Restraints & Challenges:

Immunotherapy, although its tremendous potential, confronts problems and limitations that must be carefully considered. Activating the immune system to target cancer cells can cause a variety of adverse effects, ranging from minor to severe. Notably, specific immunotherapies can trigger problems such as cytokine release syndrome (CRS) and neurotoxicity, requiring clinicians to closely monitor patients and manage these responses precisely to prevent complications.

Conventional treatments such as chemotherapy and radiation, which target rapidly dividing cancer cells, may have negative effects and may be ineffective in some cases. Chemotherapy can cause a variety of side effects, including nausea and exhaustion, and can harm both healthy and malignant cells. The limits of these approaches emphasize the need for novel and personalized treatments.

Type Segment Insights and Analysis:

Based on the type, the hematologic malignancies market is segmented into leukemia, lymphoma, myeloma, and others.

Leukemia segment contributed the largest market share during the forecasted period. It has been sub-segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. According to the American Cancer Society, in 2025, a projected 66,890 new cases of leukemia would be identified in the US, resulting in 23,540 deaths. Adults (20+) are more likely to develop CLL (38%) and AML (31%), while children and adolescents (0-19) are more likely to develop ALL (76%) and AML (16%).

AML makes for around one-third of adult leukemias and 1% of all malignancies. AML can occur in children; however, it is uncommon in those under the age of 45. The average age of persons who are first diagnosed with AML is around 69. Although men are significantly more likely to get AML than women, both sexes have an average lifetime risk of approximately ½ of 1%.

On July 2025, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has approved their supplemental new drug application (sNDA) for INQOVI (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy. The United States has approved INQOVI, an oral hypomethylating regimen, for treating people with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

Diagnosis Segment Insights and Analysis:

Based on the diagnosis, the hematologic malignancies market is segmented into blood tests, biopsy, and imaging tests.

Blood tests segment contributed the largest market share in 2024. It has been sub-segmented into complete blood count test and circulating tumor cell test. Hematologists/oncologists, hematopathologists, and radiologists all use various methods to identify blood malignancies. Several hematologic malignancies have aberrant cells, which can be discovered by analyzing blood, bone marrow, or tissue. A hematology test panel typically comprises a complete blood count, erythrocyte sedimentation rate (ESR), reticulocyte count, and bone marrow aspirate examination with a bone marrow differential count.

The most common causes of a high erythrocyte sedimentation rate are inflammation of various causes, paraproteinemic hematological malignancies, symptomatic paraproteinemia associated with malignant neoplasms, acute and chronic infections, myocardial infarction, anemia, surgical treatments, hypoproteinosis etc.

On May 2023, Siemens Healthineers has unveiled next-generation hematology analyzers, with workflow bottlenecks reduced to help patients receive results faster.  The Atellica HEMA 570 and 580 Analyzers provide easy interfaces and multi-analyzer automation connectivity to reduce workflow bottlenecks and achieve the quick throughput that high-volume labs require. The Atellica HEMA 570 and HEMA 580 Analyzers have a capacity of up to 120 tests per hour. Their user-friendly designs considerably minimize time-consuming daily maintenance while allowing very quick reagent swaps.

Treatment Type Segment Insights and Analysis:

Based on the treatment type, the hematologic malignancies market is segmented into chemotherapy, radiotherapy, stem cell transplantation, and immunotherapy.

Immunotherapy segment contributed the fastest growth rate during the forecasted period. It has been sub-segmented into chimeric antigen receptor (CAR) T-cell therapy, cytokine treatment, donor lymphocyte infusion, and monoclonal antibody. The immune-cell genesis of hematologic malignancies offers a unique opportunity to better understand both immunological responsiveness and immune escape mechanisms, hastening immunotherapy advances. For instance, Natural killer (NK) cells show potential in the treatment of hematologic malignancies. One of the most distinguishing aspects of NK cells is the presence of cytoplasmic granules containing proteases and perforins. NK cells can respond immediately when they detect stress and ‘danger’ signals from foreign substances. Furthermore, NK cells modulate immunological responses by rapidly producing cytokines and chemokines, eliminating antigen-presenting cells, and activating T cells.

On July 2025, Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic (linvoseltamab-gcpt) for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma (MM). This approval applies to individuals who have previously undergone at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.

Geographical Outlook:

Hematologic malignancies market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Hematologic Malignancies Market:

North America is registered to have highest market share in hematologic malignancies market in 2024. This is mainly driven by rising incidence and prevalence of hematologic cancers and advancements in targeted and immunotherapies. According to the American Cancer Society, multiple myeloma in the United States in 2025 are: an estimated 36,110 new cases will be diagnosed (20,030 in men and 16,080 in women), and approximately 12,030 deaths are projected (6,540 in males and 5,490 in women). In the United States, the average lifetime chance of developing multiple myeloma is less than 1%, or around 1 in 108 for men and 1 in 133 for women. Multiple myeloma is particularly common in elderly adults.

On April 2025, Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, and Shilpa Medicare Limited have announced the U.S. launch of BORUZU, a novel bortezomib formulation for ready-to-use subcutaneous or intravenous (IV) administration. This new ready-to-use cancer medication eliminates the compounded preparation steps normally necessary for delivery. Healthcare providers use BORUZU (bortezomib injection), a proteasome inhibitor, to treat multiple myeloma and mantle cell lymphoma. This product replicates the branded drug Velcade, which comes as a lyophilized powder that users must reconstitute before administration. Shilpa created the molecule, while Amneal will produce and market the product.

Asia Pacific Hematologic Malignancies Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, as advancements in targeted and immunotherapies and increased government and private funding continue to boost cancer research. Additionally, healthcare providers are increasingly adopting Minimal Residual Disease (MRD) testing, which is further driving market growth. Multiple myeloma, a common type of blood cancer, develops from plasma cells in the bone marrow and accounts for approximately 10–15% of all blood malignancies. In India, researchers estimate the incidence of myeloma at around 1.0 per 100,000 people, and recent data projects that this figure will gradually rise. While only 3 to 5% of patients with multiple myeloma report a family history of the disease, the vast majority develop it without any hereditary link.

In January 2025, Immuneel Therapeutics announced the launch of Qartemi, a global CAR T-cell treatment for adult B-cell non-Hodgkin lymphoma (B-NHL). Immuneel aims to address a significant gap in the Indian cancer immunotherapy landscape by offering this personalized therapy for adult patients with relapsed or refractory B-NHL. The company has benchmarked the treatment to global standards and now provides it locally to patients who have not responded to conventional therapies such as chemotherapy.

Europe Hematologic Malignancies Market:

Europe is expected to have considerable market share in 2024. According to the Blood Cancer UK, blood cancer is the sixth most frequent malignancy in the United Kingdom, accounting for approximately 40,000 cases per year. The UK has approximately 250,000 people living with blood cancer. One in every sixteen males and one in every twenty-two women will develop it at some time in their life. It is the most prevalent form of childhood cancer. Every year, more than 500 children less than 15 are diagnosed with blood cancer. Around 400 of them have pediatric leukemia, while another 100 have lymphoma.

On April 2025, GSK plc has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Blenrep in the UK. The approval covers its use in adults with multiple myeloma in two treatment combinations: with bortezomib and dexamethasone (BVd) for patients who have undergone at least one prior therapy, and with pomalidomide and dexamethasone (BPd) for those previously treated with at least one therapy, including lenalidomide.

Competition Analysis:

The hematologic malignancies market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the hematologic malignancies market report are:

• Pfizer Inc
• Hoffmann-LA Roche Ltd
• Sanofi SA
• AbbVie Inc.
• Takeda Pharmaceutical Company 
• Novartis AG
• Johnson & Johnson Services, Inc
• Bristol-Myers Squibb Company
• GlaxoSmithKline PLC
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Astrazeneca
• Incyte 

Strategic Developments in Hematologic Malignancies Market:

• In June 2025, Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of a new indication for the subcutaneous (SC) formulation of DARZALEX (daratumumab). The recommendation supports its use as a monotherapy for adult patients with high-risk smouldering multiple myeloma (SMM) who are at increased risk of progressing to multiple myeloma.
• In June 2025, Enterome SA, a clinical-stage firm producing first-in-class OncoMimics immunotherapies for cancer treatment, has raised USD 19 million in new private investment to expand its primary clinical program, EO2463 OncoMimics immunotherapy for indolent non-Hodgkin lymphoma (iNHL). The new funding will be utilized to expand and complete the ongoing Phase 1/2 SIDNEY clinical trial of EO2463, as well as to prepare the candidate for a registrational trial.
• In November 2024, Shorla Oncology, a specialty pharmaceutical business based in the United States and Ireland, announced that the FDA has approved IMKELDI (imatinib) oral solution, the first oral liquid version of imatinib to treat specific types of leukemia and other malignancies. IMKELDI, an improved liquid formulation of imatinib based on Shorla’s innovative technology, is designed to give precise dosing. IMKELDI can help reduce or prevent the progression of some cancers, including as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, myelodysplastic syndrome/myeloproliferative disease (MDS/MPD), and gastrointestinal tumors (GIST).

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Hematologic Malignancies Market Report:

The Hematologic Malignancies market report offers a detailed analysis of market size, including historical revenue (in USD Billion) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Type Outlook (Revenue, USD Billion; 2022-2032)
  • Leukemia
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Myeloid Leukemia
  • Lymphoma
    • Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
      • B-cell Lymphoma
      • T-cell Lymphoma

• • Myeloma
  • Others

• Diagnosis Outlook (Revenue, USD Billion; 2022-2032)
  • Blood Tests
    • Complete Blood Count Test
    • Circulating Tumor Cell Test
  • Biopsy
    • Liquid Biopsy
    • Bone Marrow Biopsy
  • Imaging Tests
    • Chest X-rays
    • Computed Tomography (CT)
    • Fluorodeoxyglucose with Positron Emission Tomography (FDG-PET)
    • Magnetic Resonance Imaging (MRI)
    • Positron emission tomography-computed tomography (PET-CT)
    • Ultrasound

• Treatment Type Outlook (Revenue, USD Billion; 2022-2032)
  • Chemotherapy
    • Rituaxan/Mabthera (Rituximab)
    • Gleevac/Glivec (Imatinib)
    • Revlimid (Lenalidomide)
    • Velcade (Bortezomib)
    • Tasigna (Nilotinib)
    • Pomalyst (Pomalidomide)
    • Vidaza (Azacitidine)
    • Others
  • Radiotherapy
    • Stem Cell Transplantation
    • Immunotherapy
      • Chimeric antigen receptor (CAR) T-cell therapy
      • Cytokine Treatment
      • Donor lymphocyte infusion
      • Monoclonal Antibody

• Route of Administration Outlook (Revenue, USD Billion; 2022-2032)
  • Oral
  • Parenteral
  • Others

• End-Use Outlook (Revenue, USD Billion; 2022-2032)
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Cancer Centers
  • Pharmaceutical and Biotech Companies
  • Others

• Regional Outlook (Revenue, USD Billion; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Hematologic Malignancies market report